

About SK Life Science



We are a U.S. subsidiary of SK Biopharmaceuticals Co., Ltd., the first and only Korean company to develop, commercialize and market an innovative drug in the U.S., the world's largest pharmaceuticals and biotech market.

We have a unique understanding of central nervous system (CNS) disorders and the market-specific dynamics that impact the development and commercialization of new treatments.

Since 2017, SK Biopharmaceuticals has been strategically diversifying beyond CNS to invest in oncology helping us become a stronger company that builds upon our success.

SK Life Science and SK Biopharmaceuticals are part of SK Group, a global leader with a tradition of promoting game-changing businesses and nurturing them for long-term success. SK Group was named one of TIME's 100 Most Influential Companies of 2023.

Our Pipeline

We have a deep expertise in research and development, as well as in bringing therapies to market in the U.S. We apply this expertise to the development of potential new therapies in CNS.

When SK Biopharmaceuticals established our research center, we expanded into oncology.

We listen to the needs of patients, caregivers, healthcare providers and scientists to guide us in the development of new compounds so that we can develop solutions that change what is possible.

We currently have eight compounds in development in CNS and oncology.

COMPOUND	INDICATION	STATUS
Cenobamate	Epilepsy Focal (partial)-Onset Seizures (Asia)	Phase 3 ¹
	Epilepsy Primary Generalized Tonic-Clonic Seizures	Phase 3
Carisbamate	Lennox-Gastaut Syndrome	Phase 3
Relenopride	Rare Neurological Disease	Phase 2*
SKL24741	Epilepsy	Phase 1
SKL20540	Schizophrenia	Phase 1
SKL27969	Advanced Solid Tumor	Phase 1
SKL13865	Attention Deficit/ Hyperactivity Disorder	Phase 1*
SKL-PSY	Bipolar Disorder	Phase 1*

* Partnership

¹In 2020, SK Biopharmaceuticals, the parent company of SK Life Science, initiated a clinical development program for cenobamate in China, Japan, and South Korea.

SK Life Science

2002

SK Life Science, Inc.
Founded
in the U.S.

2005

Investigational New
Drug (IND) Submission
in the U.S.

2019

FDA New Drug
Application (NDA)
Approval

2020

Launch of Anti-Seizure
Medication (ASM)
Treatment in the U.S.

More than 100,000 patients
have been treated with our drug globally.

Estimate derived from the use of information under license from the following IQVIA service: NPA, NSP, XPD for the period May 2020-Dec. 2023.

In the U.S.,
our ASM is the fastest-growing branded
epilepsy Rx and is first among epileptologists.

According to NPA TRx 2023 vs 2022.

**We Believe There Is More To Life When
You Connect Health With Happiness.
Together, we...**

Empower Excellence

Embody a Pioneering Spirit

Are Fully Engaged

Always Do the Right Thing

Appreciate & Recognize People

Inspire Happiness!

Contact Us

General Business
Info@sklsi.com

Strategic Alliance & Partnership Opportunities
Partnerships@sklsi.com

Media Inquiries & PR
Media@sklsi.com

For more information, visit us at: www.sklifescienceinc.com

NP-US-SKLSI-0500